These latter studies will be aimed to clarify the extent to which treatment outcomes in HER2‐positive metastatic BC treated with sequences including hormonal therapy and novel anti‐HER2 agents may differ depending on the coexpression of both the HRs vs. only one of the two. The gene discussed is ERBB2; the disease is breast cancer.